However, the application of anti-IL-10R antibody requires further study, as its usage might activate oncogene XRCC5. Ongoing studies that analyse the function of tumour residential macrophage is warranted when immunisation and temporal IL-10 signalling blockade is used to treat cancer patients. Here, XRCC5 is linked to neoplasm.